-
1
-
-
78649487218
-
Transfusion-associated infections: 50 years of relentless challenges and remarkable progress
-
Perkins HA, Busch MP. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion 2010;50:2080-99.
-
(2010)
Transfusion
, vol.50
, pp. 2080-2099
-
-
Perkins, H.A.1
Busch, M.P.2
-
2
-
-
4143071570
-
Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing
-
Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004;351:760-8.
-
(2004)
N Engl J Med
, vol.351
, pp. 760-768
-
-
Stramer, S.L.1
Glynn, S.A.2
Kleinman, S.H.3
-
3
-
-
70449085441
-
Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion
-
Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009;49:2454-89.
-
(2009)
Transfusion
, vol.49
, pp. 2454-2489
-
-
Kleinman, S.H.1
Lelie, N.2
Busch, M.P.3
-
4
-
-
85065299876
-
Prevention of transfusion transmitted infections
-
Busch MP, Bloch EM, Kleinman SH. Prevention of transfusion transmitted infections. Blood. 2019;133(17):1854-64.
-
(2019)
Blood
, vol.133
, Issue.17
, pp. 1854-1864
-
-
Busch, M.P.1
Bloch, E.M.2
Kleinman, S.H.3
-
5
-
-
68149125565
-
Emerging infectious disease agents and their potential threat to transfusion safety
-
Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009;49(Suppl 2):1S-29S.
-
(2009)
Transfusion
, vol.49
, pp. 1S-29S
-
-
Stramer, S.L.1
Hollinger, F.B.2
Katz, L.M.3
-
6
-
-
84873420262
-
Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century
-
Glynn SA, Busch MP, Dodd RY, et al. Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century. Transfusion 2013;53:438-54.
-
(2013)
Transfusion
, vol.53
, pp. 438-454
-
-
Glynn, S.A.1
Busch, M.P.2
Dodd, R.Y.3
-
7
-
-
80051612913
-
FDA workshop on emerging infectious diseases: evaluating emerging infectious diseases (EIDs) for transfusion safety
-
Atreya C, Nakhasi H, Mied P, et al. FDA workshop on emerging infectious diseases: evaluating emerging infectious diseases (EIDs) for transfusion safety. Transfusion 2011;51:1855-71.
-
(2011)
Transfusion
, vol.51
, pp. 1855-1871
-
-
Atreya, C.1
Nakhasi, H.2
Mied, P.3
-
8
-
-
85059096850
-
Impact of one-time testing for Trypanosoma cruzi antibodies among blood donors in the United States
-
Dodd R, Groves JA, Townsend RL, et al. Impact of one-time testing for Trypanosoma cruzi antibodies among blood donors in the United States. Transfusion 2019;59:1016-23.
-
(2019)
Transfusion
, vol.59
, pp. 1016-1023
-
-
Dodd, R.1
Groves, J.A.2
Townsend, R.L.3
-
9
-
-
23044469979
-
Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing
-
Busch MP, Caglioti S, Robertson EF, et al. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med 2005;353:460-7.
-
(2005)
N Engl J Med
, vol.353
, pp. 460-467
-
-
Busch, M.P.1
Caglioti, S.2
Robertson, E.F.3
-
10
-
-
84930570786
-
Keeping blood transfusion safe from West Nile virus: American Red Cross Experience, 2003 to 2012
-
Dodd RY, Foster GA, Stramer SL. Keeping blood transfusion safe from West Nile virus: American Red Cross Experience, 2003 to 2012. Transfus Med Rev 2015;29:153-61.
-
(2015)
Transfus Med Rev
, vol.29
, pp. 153-161
-
-
Dodd, R.Y.1
Foster, G.A.2
Stramer, S.L.3
-
11
-
-
85013676204
-
First cases of Zika virus-infected US blood donors outside states with areas of active transmission
-
Williamson PC, Linnen JM, Kessler DA, et al. First cases of Zika virus-infected US blood donors outside states with areas of active transmission. Transfusion 2017;57(3pt2):770-8.
-
(2017)
Transfusion
, vol.57
, Issue.3pt2
, pp. 770-778
-
-
Williamson, P.C.1
Linnen, J.M.2
Kessler, D.A.3
-
12
-
-
85046961659
-
Investigational testing for Zika Virus among U.S. blood donors
-
Saa P, Proctor M, Foster G, et al. Investigational testing for Zika Virus among U.S. blood donors. N Engl J Med 2018;378:1778-88.
-
(2018)
N Engl J Med
, vol.378
, pp. 1778-1788
-
-
Saa, P.1
Proctor, M.2
Foster, G.3
-
13
-
-
85003748575
-
Screening for Babesia microti in the U.S. Blood Supply
-
Moritz ED, Winton CS, Tonnetti L, et al. Screening for Babesia microti in the U.S. Blood Supply. N Engl J Med 2016;375:2236-45.
-
(2016)
N Engl J Med
, vol.375
, pp. 2236-2245
-
-
Moritz, E.D.1
Winton, C.S.2
Tonnetti, L.3
-
14
-
-
85053034044
-
Assessing the risk of Babesia to the United States blood supply using a risk-based decision-making approach: Report of AABB's Ad Hoc Babesia Policy Working Group (original report)
-
Ward SJ, Stramer SL, Szczepiorkowski ZM. Assessing the risk of Babesia to the United States blood supply using a risk-based decision-making approach: Report of AABB's Ad Hoc Babesia Policy Working Group (original report). Transfusion 2018;58:1916-23.
-
(2018)
Transfusion
, vol.58
, pp. 1916-1923
-
-
Ward, S.J.1
Stramer, S.L.2
Szczepiorkowski, Z.M.3
-
15
-
-
85021339267
-
Residual risk of bacterial contamination of platelets: six years of experience with sterility testing
-
Ramirez-Arcos S, DiFranco C, McIntyre T, et al. Residual risk of bacterial contamination of platelets: six years of experience with sterility testing. Transfusion 2017;57:2174-81.
-
(2017)
Transfusion
, vol.57
, pp. 2174-2181
-
-
Ramirez-Arcos, S.1
DiFranco, C.2
McIntyre, T.3
-
16
-
-
84952685517
-
Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK Transfusion Medicine Epidemiology Review Study
-
Urwin PJ, Mackenzie JM, Llewelyn CA, et al. Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK Transfusion Medicine Epidemiology Review Study. Vox Sang 2016;110:310-6.
-
(2016)
Vox Sang
, vol.110
, pp. 310-316
-
-
Urwin, P.J.1
Mackenzie, J.M.2
Llewelyn, C.A.3
-
17
-
-
70350488874
-
Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome
-
Lombardi VC, Ruscetti FW, Das Gupta J, et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009;326:585-9.
-
(2009)
Science
, vol.326
, pp. 585-589
-
-
Lombardi, V.C.1
Ruscetti, F.W.2
Das Gupta, J.3
-
18
-
-
81055140369
-
Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study
-
Simmons G, Glynn SA, Komaroff AL, et al. Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science 2011;334:814-7.
-
(2011)
Science
, vol.334
, pp. 814-817
-
-
Simmons, G.1
Glynn, S.A.2
Komaroff, A.L.3
-
19
-
-
85053510347
-
Risk-based decision-making in transfusion medicine
-
Bennett JL, Devine DV. Risk-based decision-making in transfusion medicine. Vox Sang 2018;113:737-49.
-
(2018)
Vox Sang
, vol.113
, pp. 737-749
-
-
Bennett, J.L.1
Devine, D.V.2
-
20
-
-
85046966482
-
Revisiting blood safety practices given emerging data about Zika virus
-
Bloch EM, Ness PM, Tobian AAR, et al. Revisiting blood safety practices given emerging data about Zika virus. N Engl J Med 2018;378:1837-41.
-
(2018)
N Engl J Med
, vol.378
, pp. 1837-1841
-
-
Bloch, E.M.1
Ness, P.M.2
Tobian, A.A.R.3
-
25
-
-
84957539268
-
Chemical and biological mechanisms of pathogen reduction technologies
-
Mundt J, Rouse L, Van den Bossche J, et al. Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol 2014;90:957-64.
-
(2014)
Photochem Photobiol
, vol.90
, pp. 957-964
-
-
Mundt, J.1
Rouse, L.2
Van den Bossche, J.3
-
26
-
-
84906559343
-
Pathogen inactivation technologies for cellular blood components: an update
-
Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014;41:309-25.
-
(2014)
Transfus Med Hemother
, vol.41
, pp. 309-325
-
-
Schlenke, P.1
-
27
-
-
85061835969
-
Pathogen inactivation of cellular blood products- an additional safety layer in transfusion medicine
-
Seltam A. Pathogen inactivation of cellular blood products- an additional safety layer in transfusion medicine. Front Med (Lausanne) 2017;4:219.
-
(2017)
Front Med (Lausanne)
, vol.4
, pp. 219
-
-
Seltam, A.1
-
28
-
-
85066831902
-
-
Terumo BCT announces enrollment of the first patient in its U.S. clinical trial designed to study platelets treated with the Mirasol® pathogen reduction technology (PRT) system [Internet]. Lakewood (CO) Terumo BCT; 2017. Available from
-
Terumo BCT. Terumo BCT announces enrollment of the first patient in its U.S. clinical trial designed to study platelets treated with the Mirasol® pathogen reduction technology (PRT) system [Internet]. Lakewood (CO): Terumo BCT; 2017. Available from: https://www.terumobct.com/Pages/News/Press%20Releases/Terumo-BCT-Announces-Enrollment-of-the-First-Patient--in-Its-U-S--Clinical-Trial-Designed-to-Study-Platelets-Treated--With-.aspx.
-
-
-
Terumo, B.C.T.1
-
29
-
-
84931567550
-
Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction- a phase I clinical trial
-
Thiele T, Pohler P, Kohlmann T, et al. Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction- a phase I clinical trial. Vox Sang 2015;109:44-51.
-
(2015)
Vox Sang
, vol.109
, pp. 44-51
-
-
Thiele, T.1
Pohler, P.2
Kohlmann, T.3
-
30
-
-
85053197550
-
Pathogen-inactivated blood products for pediatric patients: blood safety, patient safety, or both?
-
Jaquot C, Delaney M. Pathogen-inactivated blood products for pediatric patients: blood safety, patient safety, or both? Transfusion 2018;58:2095-101.
-
(2018)
Transfusion
, vol.58
, pp. 2095-2101
-
-
Jaquot, C.1
Delaney, M.2
-
31
-
-
85007360645
-
Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian regional medical center
-
Amato M, Schennach H, Astl M, et al. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian regional medical center. Vox Sang 2017;112:47-55.
-
(2017)
Vox Sang
, vol.112
, pp. 47-55
-
-
Amato, M.1
Schennach, H.2
Astl, M.3
-
32
-
-
85013170768
-
Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients
-
Nussbaumer W, Amato M, Schennach H, et al. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients. Vox Sang 2017;112:249-56.
-
(2017)
Vox Sang
, vol.112
, pp. 249-256
-
-
Nussbaumer, W.1
Amato, M.2
Schennach, H.3
-
33
-
-
84944271950
-
A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Swissmedic Haemovigilance Annual Report 2014
-
Knutson F, Osselaer J, Pierelli L, et al. A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Swissmedic Haemovigilance Annual Report 2014. Vox Sang 2015;109:343-52.
-
(2015)
Vox Sang
, vol.109
, pp. 343-352
-
-
Knutson, F.1
Osselaer, J.2
Pierelli, L.3
-
34
-
-
85065128334
-
Transfusion reaction rates of pathogen reduced (PR) vs conventional (CONV) platelets in adults: a single academic center experience
-
Gokhale A, Schulz W, Bahar B, et al. Transfusion reaction rates of pathogen reduced (PR) vs conventional (CONV) platelets in adults: a single academic center experience. Transfusion 2018;58(S2). https://onlinelibrary.wiley.com/doi/10.1111/trf.14903):6A-254A.
-
(2018)
Transfusion
, vol.58
, Issue.S2
, pp. 6A-254A
-
-
Gokhale, A.1
Schulz, W.2
Bahar, B.3
-
35
-
-
85065128334
-
A retrospective evaluation of the hemostatic efficacy of pathogen reduced (PR) vs conventional (CONV) platelets at an academic medical center
-
Gehrie E, Schulz W, Young P, et al. A retrospective evaluation of the hemostatic efficacy of pathogen reduced (PR) vs conventional (CONV) platelets at an academic medical center. Transfusion 2018;58(S2). https://onlinelibrary.wiley.com/doi/10.1111/trf.14903):6A-254A.
-
(2018)
Transfusion
, vol.58
, Issue.S2
, pp. 6A-254A
-
-
Gehrie, E.1
Schulz, W.2
Young, P.3
-
36
-
-
85065128334
-
Transfusion of pathogen reduced (PR) vs conventional (CONV) platelets in pediatric patients: an assessment of platelet usage and incidence of transfusion reactions
-
Schulz W, Gokhale A, McPadden J, et al. Transfusion of pathogen reduced (PR) vs conventional (CONV) platelets in pediatric patients: an assessment of platelet usage and incidence of transfusion reactions. Transfusion 2018;58(S2). https://onlinelibrary.wiley.com/doi/10.1111/trf.14903):6A-254A.
-
(2018)
Transfusion
, vol.58
, Issue.S2
, pp. 6A-254A
-
-
Schulz, W.1
Gokhale, A.2
McPadden, J.3
-
37
-
-
84943818347
-
Cost implications of implementation of pathogen-inactivated platelets
-
McCullough J, Goldfinger D, Gorlin J, et al. Cost implications of implementation of pathogen-inactivated platelets. Transfusion 2015;55:2312-20.
-
(2015)
Transfusion
, vol.55
, pp. 2312-2320
-
-
McCullough, J.1
Goldfinger, D.2
Gorlin, J.3
-
38
-
-
85050982980
-
Economic implications of pathogen reduced and bacterially tested platelet components: a US hospital budget impact model
-
Prioli K, Katz J, Lyons N, et al. Economic implications of pathogen reduced and bacterially tested platelet components: a US hospital budget impact model. Appl Health Econ Health Policy 2018;16:889-99.
-
(2018)
Appl Health Econ Health Policy
, vol.16
, pp. 889-899
-
-
Prioli, K.1
Katz, J.2
Lyons, N.3
-
39
-
-
23844453081
-
Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital factor deficiencies
-
de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital factor deficiencies. Transfusion 2005;45:1362-72.
-
(2005)
Transfusion
, vol.45
, pp. 1362-1372
-
-
de Alarcon, P.1
Benjamin, R.2
Dugdale, M.3
-
40
-
-
85066872574
-
Quantitative analysis of plasma proteins in whole-blood derived fresh frozen plasma prepare with three pathogen reduction technologies
-
Larrea L, Ortiz-de-Salazar M-I, Martinez P, et al. Quantitative analysis of plasma proteins in whole-blood derived fresh frozen plasma prepare with three pathogen reduction technologies. Transfus Apher Sci 2009;41:199-204.
-
(2009)
Transfus Apher Sci
, vol.41
, pp. 199-204
-
-
Larrea, L.1
Ortiz-de-Salazar, M.-I.2
Martinez, P.3
-
41
-
-
77950239200
-
Protein quality in Mirasol pathogen reduction technology-treated apheresis-derived fresh-frozen plasma
-
Smith J, Rock G. Protein quality in Mirasol pathogen reduction technology-treated apheresis-derived fresh-frozen plasma. Transfusion 2010;50:926-31.
-
(2010)
Transfusion
, vol.50
, pp. 926-931
-
-
Smith, J.1
Rock, G.2
-
42
-
-
84900483776
-
Paired analysis of plasma proteins and coagulation capacity after treatment with three methods of pathogen reduction
-
Coene J, Devreese K, Sabot B, et al. Paired analysis of plasma proteins and coagulation capacity after treatment with three methods of pathogen reduction. Transfusion 2014;54:1321-31.
-
(2014)
Transfusion
, vol.54
, pp. 1321-1331
-
-
Coene, J.1
Devreese, K.2
Sabot, B.3
-
43
-
-
70350462130
-
Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins
-
Hornsy VS, Drummond O, Morrison A, et al. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins. Transfusion 2009;49:2167-72.
-
(2009)
Transfusion
, vol.49
, pp. 2167-2172
-
-
Hornsy, V.S.1
Drummond, O.2
Morrison, A.3
-
44
-
-
85005900899
-
Quarantine versus pathogen-reduced plasma-coagulation factor content and rotational thromboelastometry coagulation
-
Theusinger OM, Goslings D, Studt J-D, et al. Quarantine versus pathogen-reduced plasma-coagulation factor content and rotational thromboelastometry coagulation. Transfusion 2017;57:637-45.
-
(2017)
Transfusion
, vol.57
, pp. 637-645
-
-
Theusinger, O.M.1
Goslings, D.2
Studt, J.-D.3
-
45
-
-
73649129231
-
Intercept plasma: comparability with conventional fresh-frozen plasma based on coagulation function - an in vitro analysis
-
Irsch J, Pinkosky L, Corash L, et al. Intercept plasma: comparability with conventional fresh-frozen plasma based on coagulation function - an in vitro analysis. Vox Sang 2010;98:47-55.
-
(2010)
Vox Sang
, vol.98
, pp. 47-55
-
-
Irsch, J.1
Pinkosky, L.2
Corash, L.3
-
46
-
-
55149111374
-
Indications for use and cost-effectiveness of pathogen-reduced ABO-universal plasma
-
Solheim BG, Chetty R, Flesland O. Indications for use and cost-effectiveness of pathogen-reduced ABO-universal plasma. Curr Opin Hematol 2008;15:612-7.
-
(2008)
Curr Opin Hematol
, vol.15
, pp. 612-617
-
-
Solheim, B.G.1
Chetty, R.2
Flesland, O.3
-
47
-
-
84874949948
-
Quantitative and qualitative analysis of coagulation factors in cryoprecipitate prepared from fresh-frozen plasma inactivated with amotosalen and ultraviolet A light
-
Cid J, Caballo C, Pino M, et al. Quantitative and qualitative analysis of coagulation factors in cryoprecipitate prepared from fresh-frozen plasma inactivated with amotosalen and ultraviolet A light. Transfusion 2013;53:600-5.
-
(2013)
Transfusion
, vol.53
, pp. 600-605
-
-
Cid, J.1
Caballo, C.2
Pino, M.3
-
48
-
-
84858285463
-
Preparation of cryoprecipitate from riboflavin and UV-light treated plasma
-
Ettinger A, Miklauz MM, Bihm DJ, et al. Preparation of cryoprecipitate from riboflavin and UV-light treated plasma. Transfus Apher Sci 2012;46:153-8.
-
(2012)
Transfus Apher Sci
, vol.46
, pp. 153-158
-
-
Ettinger, A.1
Miklauz, M.M.2
Bihm, D.J.3
-
49
-
-
84954401850
-
Effect of riboflavin and amotosalen photoactivation systems for pathogen inactivation of fresh-frozen plasma on fibrin clot structure
-
Hubbard T, Backholer L, Wiltshire M, et al. Effect of riboflavin and amotosalen photoactivation systems for pathogen inactivation of fresh-frozen plasma on fibrin clot structure. Transfusion 2016;56:41-8.
-
(2016)
Transfusion
, vol.56
, pp. 41-48
-
-
Hubbard, T.1
Backholer, L.2
Wiltshire, M.3
-
50
-
-
84937022864
-
Comparative effectiveness of plasma prepared with amotosalen-UVA pathogen inactivation and conventional plasma for support of liver transplantation
-
Cinqualbre J, Kientz D, Remy E, et al. Comparative effectiveness of plasma prepared with amotosalen-UVA pathogen inactivation and conventional plasma for support of liver transplantation. Transfusion 2015;55:1710-20.
-
(2015)
Transfusion
, vol.55
, pp. 1710-1720
-
-
Cinqualbre, J.1
Kientz, D.2
Remy, E.3
-
51
-
-
33748950122
-
A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura
-
Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006;46:1693-704.
-
(2006)
Transfusion
, vol.46
, pp. 1693-1704
-
-
Mintz, P.D.1
Neff, A.2
MacKenzie, M.3
-
52
-
-
85034993425
-
Amotosalen-inactivated plasma is equally well tolerated as quarantine plasma in patients undergoing large volume therapeutic plasma exchange
-
Guignier C, Benamara A, Oriol P, et al. Amotosalen-inactivated plasma is equally well tolerated as quarantine plasma in patients undergoing large volume therapeutic plasma exchange. Transfus Clin Biol 2018;25:73-7.
-
(2018)
Transfus Clin Biol
, vol.25
, pp. 73-77
-
-
Guignier, C.1
Benamara, A.2
Oriol, P.3
-
53
-
-
84908226307
-
Low incidence of hyperfibrinolysis and thromboembolism in 195 primary liver transplantations transfused with solvent/detergent-treated plasma
-
Haugaa H, Taraldsrud E, Nyrerød HC, et al. Low incidence of hyperfibrinolysis and thromboembolism in 195 primary liver transplantations transfused with solvent/detergent-treated plasma. Clin Med Res 2014;12:27-32.
-
(2014)
Clin Med Res
, vol.12
, pp. 27-32
-
-
Haugaa, H.1
Taraldsrud, E.2
Nyrerød, H.C.3
-
54
-
-
0037600705
-
Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura
-
Yarranton H, Cohen H, Pavord SR, et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003;121:778-85.
-
(2003)
Br J Haematol
, vol.121
, pp. 778-785
-
-
Yarranton, H.1
Cohen, H.2
Pavord, S.R.3
-
55
-
-
84966668103
-
Will pathogen reduction of blood components harm more people than it helps in developed countries
-
Hess JR, Pagano MB, Barbeau JD, et al. Will pathogen reduction of blood components harm more people than it helps in developed countries. Transfusion 2016;56:1236-41.
-
(2016)
Transfusion
, vol.56
, pp. 1236-1241
-
-
Hess, J.R.1
Pagano, M.B.2
Barbeau, J.D.3
-
56
-
-
85013807573
-
Pathogen inactivation treatment of plasma and platelet concentrates and their predicted functionality in massive transfusion protocols
-
Arbaeen AF, Schubert P, Serrano K, et al. Pathogen inactivation treatment of plasma and platelet concentrates and their predicted functionality in massive transfusion protocols. Transfusion 2017;57:1208-17.
-
(2017)
Transfusion
, vol.57
, pp. 1208-1217
-
-
Arbaeen, A.F.1
Schubert, P.2
Serrano, K.3
-
57
-
-
85026761733
-
Comparing transfusion reaction rates for various plasma types: a systematic review and meta-analysis/regression
-
Saadah NH, van Hout FMA, Schipperus NR, et al. Comparing transfusion reaction rates for various plasma types: a systematic review and meta-analysis/regression. Transfusion 2017;57:2104-14.
-
(2017)
Transfusion
, vol.57
, pp. 2104-2114
-
-
Saadah, N.H.1
van Hout, F.M.A.2
Schipperus, N.R.3
-
58
-
-
33748475913
-
Update on pathogen reduction technology for therapeutic plasma: an overview
-
Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transf Apher Sci 2006;35:83-90.
-
(2006)
Transf Apher Sci
, vol.35
, pp. 83-90
-
-
Solheim, B.G.1
Seghatchian, J.2
-
59
-
-
79851482225
-
The use of solvent/detergent treatment in pathogen reduction of plamsa
-
Hellstern P, Solheim BG. The use of solvent/detergent treatment in pathogen reduction of plamsa. Transf Med Hemother 2011;38:65-70.
-
(2011)
Transf Med Hemother
, vol.38
, pp. 65-70
-
-
Hellstern, P.1
Solheim, B.G.2
-
60
-
-
0041639518
-
Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma
-
Riedler GF, Haycox AR, Duggan AK, et al. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003;85:88-95.
-
(2003)
Vox Sang
, vol.85
, pp. 88-95
-
-
Riedler, G.F.1
Haycox, A.R.2
Duggan, A.K.3
-
61
-
-
84942949484
-
Safety and cost-effectiveness of solvent-detergent treated plasma. In search of a zero-risk blood supply
-
AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent-detergent treated plasma. In search of a zero-risk blood supply. JAMA 1994;272:1210-4.
-
(1994)
JAMA
, vol.272
, pp. 1210-1214
-
-
AuBuchon, J.P.1
Birkmeyer, J.D.2
-
62
-
-
84891702001
-
Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress
-
Stramer SL, Dodd RY. Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress. Transfusion 2013;53:2375-83.
-
(2013)
Transfusion
, vol.53
, pp. 2375-2383
-
-
Stramer, S.L.1
Dodd, R.Y.2
-
63
-
-
80053969260
-
The NIH Clinical Center and the future of clinical research
-
Gallin JI. The NIH Clinical Center and the future of clinical research. Nat Med 2011;17:1221-3.
-
(2011)
Nat Med
, vol.17
, pp. 1221-1223
-
-
Gallin, J.I.1
-
64
-
-
85047452388
-
Pathogen inactivation strategies to improve blood safety: let's not throw pathogen-reduced platelets out with their bath water
-
Devine DV. Pathogen inactivation strategies to improve blood safety: let's not throw pathogen-reduced platelets out with their bath water. JAMA Oncol 2018;4:458-9.
-
(2018)
JAMA Oncol
, vol.4
, pp. 458-459
-
-
Devine, D.V.1
-
65
-
-
84859748210
-
Spray: single-donor plasma product for room temperature storage
-
Booth GS, Lozier JN, Nghiem K, et al. Spray: single-donor plasma product for room temperature storage. Transfusion 2012;52:828-33.
-
(2012)
Transfusion
, vol.52
, pp. 828-833
-
-
Booth, G.S.1
Lozier, J.N.2
Nghiem, K.3
-
66
-
-
0026543642
-
Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma
-
Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826-31.
-
(1992)
Blood
, vol.79
, pp. 826-831
-
-
Horowitz, B.1
Bonomo, R.2
Prince, A.M.3
-
67
-
-
78349253751
-
The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model
-
Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010;50:2461-73.
-
(2010)
Transfusion
, vol.50
, pp. 2461-2473
-
-
Custer, B.1
Agapova, M.2
Martinez, R.H.3
-
68
-
-
85052675565
-
Addressing gaps in international blood availability and transfusion safety in low- and middle-income countries: a NHLBI workshop
-
Custer B, Zou S, Glynn SA, et al. Addressing gaps in international blood availability and transfusion safety in low- and middle-income countries: a NHLBI workshop. Transfusion 2018;58:1307-17.
-
(2018)
Transfusion
, vol.58
, pp. 1307-1317
-
-
Custer, B.1
Zou, S.2
Glynn, S.A.3
-
69
-
-
85047415487
-
Nationwide implementation of pathogen inactivation for all platelet concentrates in Switzerland
-
Jutzi M, Mansouri Taleghani B, Rueesch M, et al. Nationwide implementation of pathogen inactivation for all platelet concentrates in Switzerland. Transfus Med Hemother 2018;45:151-6.
-
(2018)
Transfus Med Hemother
, vol.45
, pp. 151-156
-
-
Jutzi, M.1
Mansouri Taleghani, B.2
Rueesch, M.3
-
70
-
-
0027980227
-
Cellular gene therapy: an overview
-
Klein HG. Cellular gene therapy: an overview. J Clin Apher 1994;9:139-41.
-
(1994)
J Clin Apher
, vol.9
, pp. 139-141
-
-
Klein, H.G.1
-
71
-
-
0023918549
-
Technical aspects of lymphokine-activated killer cell production
-
Carter CS, Leitman SF, Cullis H, et al. Technical aspects of lymphokine-activated killer cell production. J Clin Apher 1988;4:113-7.
-
(1988)
J Clin Apher
, vol.4
, pp. 113-117
-
-
Carter, C.S.1
Leitman, S.F.2
Cullis, H.3
-
72
-
-
0028318470
-
Immunologic aspects of blood transfusion
-
Klein HG. Immunologic aspects of blood transfusion. Semin Oncol 1994;21:16-20.
-
(1994)
Semin Oncol
, vol.21
, pp. 16-20
-
-
Klein, H.G.1
-
73
-
-
0034109924
-
Leukocyte depletion of red cell components prevents exposure of transfusion recipients to neutrophil elastase
-
Willy C, Reithmeier W, Kuhlmann WD, et al. Leukocyte depletion of red cell components prevents exposure of transfusion recipients to neutrophil elastase. Vox Sang 2000;78:19-27.
-
(2000)
Vox Sang
, vol.78
, pp. 19-27
-
-
Willy, C.1
Reithmeier, W.2
Kuhlmann, W.D.3
-
74
-
-
85066841062
-
Transfusion of fresh vs. older red blood cells in the context of infection
-
Klein H, Natanson C, Flegel W. Transfusion of fresh vs. older red blood cells in the context of infection. ISBT Sci Ser 2015;10:275-85.
-
(2015)
ISBT Sci Ser
, vol.10
, pp. 275-285
-
-
Klein, H.1
Natanson, C.2
Flegel, W.3
-
75
-
-
84896049579
-
Does prolonged storage of red blood cells cause harm?
-
Flegel WA, Natanson C, Klein HG. Does prolonged storage of red blood cells cause harm? Br J Haematol 2014;165:3-16.
-
(2014)
Br J Haematol
, vol.165
, pp. 3-16
-
-
Flegel, W.A.1
Natanson, C.2
Klein, H.G.3
-
76
-
-
84924571547
-
Pathogen inactivation or pathogen reduction: proposal for standardization of nomenclature
-
Lozano M, Cid J, Prowse C, et al. Pathogen inactivation or pathogen reduction: proposal for standardization of nomenclature. Transfusion 2015;55:690.
-
(2015)
Transfusion
, vol.55
, pp. 690
-
-
Lozano, M.1
Cid, J.2
Prowse, C.3
-
77
-
-
0034641197
-
Will blood transfusion ever be safe enough?
-
Klein HG. Will blood transfusion ever be safe enough? JAMA 2000;284:238-40.
-
(2000)
JAMA
, vol.284
, pp. 238-240
-
-
Klein, H.G.1
-
78
-
-
66549119064
-
Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop
-
Klein HG, Glynn SA, Ness PM, et al. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. Transfusion 2009;49:1262-8.
-
(2009)
Transfusion
, vol.49
, pp. 1262-1268
-
-
Klein, H.G.1
Glynn, S.A.2
Ness, P.M.3
-
79
-
-
85066879488
-
Changes to the 30th edition of Standards for Blood Banks and Transfusion Services
-
Regan D, Markowitz MA. Changes to the 30th edition of Standards for Blood Banks and Transfusion Services. AABB Association Bulletin 2016;#16-05:1-4.
-
(2016)
AABB Association Bulletin
, vol.16-5
, pp. 1-4
-
-
Regan, D.1
Markowitz, M.A.2
-
80
-
-
84929377783
-
The safety of the blood supply - time to raise the bar
-
Snyder EL, Stramer SL, Benjamin RJ. The safety of the blood supply - time to raise the bar. N Engl J Med 2015;372:1882-5.
-
(2015)
N Engl J Med
, vol.372
, pp. 1882-1885
-
-
Snyder, E.L.1
Stramer, S.L.2
Benjamin, R.J.3
-
81
-
-
85066853147
-
Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coat
-
van Rhenen DJ, Vermeij J, Mayaudon V, et al. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coat. Vox Sang 2000;76:209-14.
-
(2000)
Vox Sang
, vol.76
, pp. 209-214
-
-
van Rhenen, D.J.1
Vermeij, J.2
Mayaudon, V.3
-
82
-
-
84875579333
-
In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system
-
Johnson L, Loh YS, Kwok M, et al. In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system. Transfus Med 2013;23:121-9.
-
(2013)
Transfus Med
, vol.23
, pp. 121-129
-
-
Johnson, L.1
Loh, Y.S.2
Kwok, M.3
-
83
-
-
1642394887
-
Functional characteristics of buffy coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation
-
Picker SM, Speer R, Gathof BS. Functional characteristics of buffy coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004;44:320-9.
-
(2004)
Transfusion
, vol.44
, pp. 320-329
-
-
Picker, S.M.1
Speer, R.2
Gathof, B.S.3
-
84
-
-
84926472995
-
Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method
-
Schubert P, Culibrk B, Karwal S, et al. Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method. Transfusion 2015;55:815-23.
-
(2015)
Transfusion
, vol.55
, pp. 815-823
-
-
Schubert, P.1
Culibrk, B.2
Karwal, S.3
-
85
-
-
84922783109
-
Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function
-
Osman A, Hitzler WE, Meyer CU, et al. Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets 2015;26:154-63.
-
(2015)
Platelets
, vol.26
, pp. 154-163
-
-
Osman, A.1
Hitzler, W.E.2
Meyer, C.U.3
-
86
-
-
84987660523
-
Riboflavin and ultraviolet illumination affects selected platelet mRNA transcript amounts differently
-
Klein-Bosgoed C, Schubert P, Devine DV. Riboflavin and ultraviolet illumination affects selected platelet mRNA transcript amounts differently. Transfusion 2016;56:2286-95.
-
(2016)
Transfusion
, vol.56
, pp. 2286-2295
-
-
Klein-Bosgoed, C.1
Schubert, P.2
Devine, D.V.3
-
87
-
-
85073837450
-
Increased cytokine release from platelet concentrates following riboflavin/UV light treatment accelerates endothelial cell proliferation and migration
-
Schubert P, Culibrk B, Lautens B, et al. Increased cytokine release from platelet concentrates following riboflavin/UV light treatment accelerates endothelial cell proliferation and migration. Transfusion 2013;53(suppl):S84-040A.
-
(2013)
Transfusion
, vol.53
, pp. S84-040A
-
-
Schubert, P.1
Culibrk, B.2
Lautens, B.3
-
88
-
-
0037443546
-
Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial
-
van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
-
(2003)
Blood
, vol.101
, pp. 2426-2433
-
-
van Rhenen, D.1
Gulliksson, H.2
Cazenave, J.P.3
-
89
-
-
4444380592
-
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial
-
McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004;104:1534-41.
-
(2004)
Blood
, vol.104
, pp. 1534-1541
-
-
McCullough, J.1
Vesole, D.H.2
Benjamin, R.J.3
-
90
-
-
85047446533
-
Pathogen reduced platelets for the prevention of bleeding in people of any age
-
Estcourt LJ, Malouf R, Murphy MF. Pathogen reduced platelets for the prevention of bleeding in people of any age. JAMA Oncol 2018;4:571-2.
-
(2018)
JAMA Oncol
, vol.4
, pp. 571-572
-
-
Estcourt, L.J.1
Malouf, R.2
Murphy, M.F.3
-
91
-
-
85047476557
-
Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) Study Group. Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases: a randomized clinical trial
-
Garban F, Guyard A, Labussière H, et al. Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) Study Group. Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases: a randomized clinical trial. JAMA Oncol 2018;4:468-75.
-
(2018)
JAMA Oncol
, vol.4
, pp. 468-475
-
-
Garban, F.1
Guyard, A.2
Labussière, H.3
-
92
-
-
85048103316
-
Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial
-
van der Meer PF, Ypma PF, van Geloven N, et al. Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial. Blood 2018;132:223-31.
-
(2018)
Blood
, vol.132
, pp. 223-231
-
-
van der Meer, P.F.1
Ypma, P.F.2
van Geloven, N.3
-
93
-
-
84944271950
-
A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment
-
Knutson F, Osselaer J, Pierelli L, et al. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 2015;109:343-52.
-
(2015)
Vox Sang
, vol.109
, pp. 343-352
-
-
Knutson, F.1
Osselaer, J.2
Pierelli, L.3
-
94
-
-
84929069313
-
Solvent/detergent-treated plasma: a tale of 30 years of experience
-
Liumbruno GM, Marano G, Grazzini G, et al. Solvent/detergent-treated plasma: a tale of 30 years of experience. Expert Rev Hematol 2015;8:367-74.
-
(2015)
Expert Rev Hematol
, vol.8
, pp. 367-374
-
-
Liumbruno, G.M.1
Marano, G.2
Grazzini, G.3
-
95
-
-
84876742256
-
A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France
-
Bost V, Odent-Malaure H, Chavarin P, et al. A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France. Vox Sang 2013;104:337-41.
-
(2013)
Vox Sang
, vol.104
, pp. 337-341
-
-
Bost, V.1
Odent-Malaure, H.2
Chavarin, P.3
-
96
-
-
0002371605
-
Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery
-
Haubelt H, Blome M, Kiessling AH, et al. Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 2002;82:9-14.
-
(2002)
Vox Sang
, vol.82
, pp. 9-14
-
-
Haubelt, H.1
Blome, M.2
Kiessling, A.H.3
-
97
-
-
34547808148
-
Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura
-
Scully M, Longair I, Flynn M, et al. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 2007;93:154-8.
-
(2007)
Vox Sang
, vol.93
, pp. 154-158
-
-
Scully, M.1
Longair, I.2
Flynn, M.3
-
98
-
-
20544468386
-
Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection
-
Solheim BG, Granov DA, Juravlev VA, et al. Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection. Vox Sang 2005;89:19-26.
-
(2005)
Vox Sang
, vol.89
, pp. 19-26
-
-
Solheim, B.G.1
Granov, D.A.2
Juravlev, V.A.3
-
99
-
-
84943739625
-
Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study
-
Toussaint-Hacquard M, Coppo P, Soudant M, et al. Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study. Transfusion 2015;55:2445-51.
-
(2015)
Transfusion
, vol.55
, pp. 2445-2451
-
-
Toussaint-Hacquard, M.1
Coppo, P.2
Soudant, M.3
-
100
-
-
84997419183
-
A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy
-
Vendramin C, McGuckin S, Alwan F, et al. A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy. Transfusion 2017;57:131-6.
-
(2017)
Transfusion
, vol.57
, pp. 131-136
-
-
Vendramin, C.1
McGuckin, S.2
Alwan, F.3
-
101
-
-
85011587144
-
Changes in hemostasis caused by different replacement fluids and outcome in therapeutic plasma exchange in pediatric patients in a retrospective single center study
-
Witt V, Pichler H, Beiglboeck E, et al. Changes in hemostasis caused by different replacement fluids and outcome in therapeutic plasma exchange in pediatric patients in a retrospective single center study. Transfus Apher Sci 2017;56:59-65.
-
(2017)
Transfus Apher Sci
, vol.56
, pp. 59-65
-
-
Witt, V.1
Pichler, H.2
Beiglboeck, E.3
-
102
-
-
0036232969
-
Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP)
-
de Jonge J, Groenland TH, Metselaar HJ, et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg 2002;94:1127-31.
-
(2002)
Anesth Analg
, vol.94
, pp. 1127-1131
-
-
de Jonge, J.1
Groenland, T.H.2
Metselaar, H.J.3
-
103
-
-
34249717261
-
Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas)
-
Magner JJ, Crowley KJ, Boylan JF. Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas). J Cardiothorac Vasc Anesth 2007;21:410-3.
-
(2007)
J Cardiothorac Vasc Anesth
, vol.21
, pp. 410-413
-
-
Magner, J.J.1
Crowley, K.J.2
Boylan, J.F.3
-
104
-
-
33751523641
-
A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment
-
Heger A, Romisch J, Svae TE. A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. Transfus Apher Sci 2006;35:223-33.
-
(2006)
Transfus Apher Sci
, vol.35
, pp. 223-233
-
-
Heger, A.1
Romisch, J.2
Svae, T.E.3
-
105
-
-
84883896424
-
Recovery, safety, and tolerability of a solvent/detergent-treated and prion-safeguarded transfusion plasma in a randomized, crossover, clinical trial in healthy volunteers
-
Jilma-Stohlawetz P, Kursten FW, Horvath M, et al. Recovery, safety, and tolerability of a solvent/detergent-treated and prion-safeguarded transfusion plasma in a randomized, crossover, clinical trial in healthy volunteers. Transfusion 2013;53:1906-17.
-
(2013)
Transfusion
, vol.53
, pp. 1906-1917
-
-
Jilma-Stohlawetz, P.1
Kursten, F.W.2
Horvath, M.3
-
106
-
-
84878919067
-
Plasma transfusion in liver transplantation: a randomized, double-blind, multicenter clinical comparison of three virally secured plasmas
-
Bartelmaos T, Chabanel A, Leger J, et al. Plasma transfusion in liver transplantation: a randomized, double-blind, multicenter clinical comparison of three virally secured plasmas. Transfusion 2013;53:1335-45.
-
(2013)
Transfusion
, vol.53
, pp. 1335-1345
-
-
Bartelmaos, T.1
Chabanel, A.2
Leger, J.3
-
107
-
-
84880298407
-
Solvent detergent vs. fresh frozen plasma in cirrhotic patients undergoing liver transplant surgery: a prospective randomized control study
-
Bindi ML, Miccoli M, Marietta M, et al. Solvent detergent vs. fresh frozen plasma in cirrhotic patients undergoing liver transplant surgery: a prospective randomized control study. Vox Sang 2013;105:137-43.
-
(2013)
Vox Sang
, vol.105
, pp. 137-143
-
-
Bindi, M.L.1
Miccoli, M.2
Marietta, M.3
-
108
-
-
85062687116
-
Resuscitation of endotheliopathy and bleeding in thoracic aortic dissections: the VIPER-OCTA randomized clinical pilot trial
-
Stensballe J, Ulrich AG, Nilsson JC, et al. Resuscitation of endotheliopathy and bleeding in thoracic aortic dissections: the VIPER-OCTA randomized clinical pilot trial. Anesth Analg 2018;127:920-7.
-
(2018)
Anesth Analg
, vol.127
, pp. 920-927
-
-
Stensballe, J.1
Ulrich, A.G.2
Nilsson, J.C.3
-
109
-
-
0242677709
-
Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery
-
Tølløfsrud S, Noddeland H, Svennevig JL, et al. Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery. Intensive Care Med 2003;29:1736-43.
-
(2003)
Intensive Care Med
, vol.29
, pp. 1736-1743
-
-
Tølløfsrud, S.1
Noddeland, H.2
Svennevig, J.L.3
-
110
-
-
0032740602
-
A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation
-
Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999;39:1227-34.
-
(1999)
Transfusion
, vol.39
, pp. 1227-1234
-
-
Williamson, L.M.1
Llewelyn, C.A.2
Fisher, N.C.3
-
111
-
-
0037206589
-
Universal solvent/detergent-treated fresh frozen plasma (Uniplas--rationale and clinical properties)
-
Noddeland H, Tollofsrud S, Svennevig J, et al. Universal solvent/detergent-treated fresh frozen plasma (Uniplas--rationale and clinical properties). Thromb Res 2002;107(Suppl 1):S33-7.
-
(2002)
Thromb Res
, vol.107
, pp. S33-S37
-
-
Noddeland, H.1
Tollofsrud, S.2
Svennevig, J.3
-
113
-
-
56849128234
-
Cost-effectiveness analysis: what it really means for transfusion medicine decision making
-
Custer B, Hoch JS. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev 2009;23:1-12.
-
(2009)
Transfus Med Rev
, vol.23
, pp. 1-12
-
-
Custer, B.1
Hoch, J.S.2
-
114
-
-
85066823630
-
Health economics and blood safety
-
Shan H, Dodd RY, , editors., New York, Springer International Publishing, p
-
Custer B. Health economics and blood safety. In: Shan H Dodd RY, editors. Blood Safety: A Guide to Monitoring and Responding to Potential New Threats. New York: Springer International Publishing; 2019. p. 53-81.
-
(2019)
Blood Safety: A Guide to Monitoring and Responding to Potential New Threats
, pp. 53-81
-
-
Custer, B.1
-
115
-
-
84930481789
-
Highlights of PBTI Coimbra Conference on PRT of plasma & current opinions on pathogen reduction treatment of blood components
-
de Sousa G, Seghatchian J. Highlights of PBTI Coimbra Conference on PRT of plasma & current opinions on pathogen reduction treatment of blood components. Transfus Apher Sci 2015;52:228-32.
-
(2015)
Transfus Apher Sci
, vol.52
, pp. 228-232
-
-
de Sousa, G.1
Seghatchian, J.2
-
116
-
-
84880703877
-
Update on the use of pathogen-reduced human plasma and platelet concentrates
-
Seltsam A, Muller TH. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013;162:442-54.
-
(2013)
Br J Haematol
, vol.162
, pp. 442-454
-
-
Seltsam, A.1
Muller, T.H.2
-
117
-
-
84875585172
-
Component pathogen inactivation: a critical review
-
Prowse CV. Component pathogen inactivation: a critical review. Vox Sang 2013;104:183-99.
-
(2013)
Vox Sang
, vol.104
, pp. 183-199
-
-
Prowse, C.V.1
-
118
-
-
85020513631
-
Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?
-
Di Minno G, Navarro D, Perno CF, et al. Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients? Ann Hematol 2017;96:1253-70.
-
(2017)
Ann Hematol
, vol.96
, pp. 1253-1270
-
-
Di Minno, G.1
Navarro, D.2
Perno, C.F.3
-
119
-
-
85021819922
-
Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology
-
Yonemura S, Doane S, Keil S, et al. Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology. Blood Transfus 2017;15:357-64.
-
(2017)
Blood Transfus
, vol.15
, pp. 357-364
-
-
Yonemura, S.1
Doane, S.2
Keil, S.3
-
120
-
-
85013498005
-
Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study
-
Cancelas JA, Gottschall JL, Rugg N, et al. Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study. Vox Sang 2017;112:210-8.
-
(2017)
Vox Sang
, vol.112
, pp. 210-218
-
-
Cancelas, J.A.1
Gottschall, J.L.2
Rugg, N.3
-
121
-
-
85031943518
-
Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries
-
Drew VJ, Barro L, Seghatchian J, et al. Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries. Blood Transfus 2017;15:512-21.
-
(2017)
Blood Transfus
, vol.15
, pp. 512-521
-
-
Drew, V.J.1
Barro, L.2
Seghatchian, J.3
-
122
-
-
84978499751
-
Quality of red cells after combination of prion reduction and treatment with the intercept system for pathogen inactivation
-
Wiltshire M, Meli A, Schott MA, et al. Quality of red cells after combination of prion reduction and treatment with the intercept system for pathogen inactivation. Transfus Med 2016;26:208-14.
-
(2016)
Transfus Med
, vol.26
, pp. 208-214
-
-
Wiltshire, M.1
Meli, A.2
Schott, M.A.3
-
123
-
-
84964413510
-
Effect of plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial
-
Allain JP, Owusu-Ofori AK, Assennato SM, et al. Effect of plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet 2016;387:1753-61.
-
(2016)
Lancet
, vol.387
, pp. 1753-1761
-
-
Allain, J.P.1
Owusu-Ofori, A.K.2
Assennato, S.M.3
-
125
-
-
85056068335
-
Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system
-
Cicchetti A, Coretti S, Sacco F, et al. Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system. Blood Transfus 2018;16:483-9.
-
(2018)
Blood Transfus
, vol.16
, pp. 483-489
-
-
Cicchetti, A.1
Coretti, S.2
Sacco, F.3
-
126
-
-
84891872378
-
Reducing the financial impact of pathogen inactivation technology for platelet components: our experience
-
Girona-Llobera E, Jimenez-Marco T, Galmes-Trueba A, et al. Reducing the financial impact of pathogen inactivation technology for platelet components: our experience. Transfusion 2014;54:158-68.
-
(2014)
Transfusion
, vol.54
, pp. 158-168
-
-
Girona-Llobera, E.1
Jimenez-Marco, T.2
Galmes-Trueba, A.3
-
127
-
-
84959489610
-
Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium
-
Walsh GM, Shih AW, Solh Z, et al. Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium. Transfus Med Rev 2016;30:53-68.
-
(2016)
Transfus Med Rev
, vol.30
, pp. 53-68
-
-
Walsh, G.M.1
Shih, A.W.2
Solh, Z.3
-
128
-
-
85044344779
-
Efforts toward elimination of infectious agents in blood products
-
Jacquot C, Delaney M. Efforts toward elimination of infectious agents in blood products. J Intensive Care Med 2018;33:543-50.
-
(2018)
J Intensive Care Med
, vol.33
, pp. 543-550
-
-
Jacquot, C.1
Delaney, M.2
-
129
-
-
70449092374
-
Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies
-
Picker SM, Schneider V, Oustianskaia L, et al. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion 2009;49:2311-8.
-
(2009)
Transfusion
, vol.49
, pp. 2311-2318
-
-
Picker, S.M.1
Schneider, V.2
Oustianskaia, L.3
-
130
-
-
85050123261
-
Ultraviolet-based pathogen inactivation systems: untangling the molecular targets activated in platelets
-
Schubert P, Johnson L, Marks DC, et al. Ultraviolet-based pathogen inactivation systems: untangling the molecular targets activated in platelets. Front Med (Lausanne) 2018;5:129.
-
(2018)
Front Med (Lausanne)
, vol.5
, pp. 129
-
-
Schubert, P.1
Johnson, L.2
Marks, D.C.3
-
131
-
-
78651284022
-
A comparison of methods of pathogen inactivation of FFP
-
Rock G. A comparison of methods of pathogen inactivation of FFP. Vox Sang 2011;100:169-78.
-
(2011)
Vox Sang
, vol.100
, pp. 169-178
-
-
Rock, G.1
-
134
-
-
40749148572
-
Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation
-
Reddy HL, Dayan AD, Cavagnaro J, et al. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008;22:133-53.
-
(2008)
Transfus Med Rev
, vol.22
, pp. 133-153
-
-
Reddy, H.L.1
Dayan, A.D.2
Cavagnaro, J.3
-
135
-
-
79851490196
-
Development of the S-303 pathogen inactivation technology for red blood cell concentrates
-
Henschler R, Seifried E, Mufti N. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother 2011;38:33-42.
-
(2011)
Transfus Med Hemother
, vol.38
, pp. 33-42
-
-
Henschler, R.1
Seifried, E.2
Mufti, N.3
-
136
-
-
85016240547
-
Whole blood pathogen reduction technology and blood safety in sub-Saharan Africa: a systematic review with regional discussion
-
Nkohkwo A, Agbor G, Asongalem E, et al. Whole blood pathogen reduction technology and blood safety in sub-Saharan Africa: a systematic review with regional discussion. Afr J Lab Med 2016;5:363.
-
(2016)
Afr J Lab Med
, vol.5
, pp. 363
-
-
Nkohkwo, A.1
Agbor, G.2
Asongalem, E.3
-
137
-
-
84937435830
-
Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections
-
Stramer SL. Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser 2014;9:30-6.
-
(2014)
ISBT Sci Ser
, vol.9
, pp. 30-36
-
-
Stramer, S.L.1
-
138
-
-
85053126632
-
Reflections on the dynamics of bacterial and viral contamination of blood components and the levels of efficacy for pathogen inactivation processes
-
Bah A, Cardoso M, Seghatchian J, et al. Reflections on the dynamics of bacterial and viral contamination of blood components and the levels of efficacy for pathogen inactivation processes. Transfus Apher Sci 2018;57:683-8. https://doi.org/10.1016/j.transci.2018.09.004.
-
(2018)
Transfus Apher Sci
, vol.57
, pp. 683-688
-
-
Bah, A.1
Cardoso, M.2
Seghatchian, J.3
-
139
-
-
85059281051
-
Interpretation of pathogen load in relationship to infectivity and pathogen reduction efficacy
-
McCullough J, Alter HJ, Ness PM. Interpretation of pathogen load in relationship to infectivity and pathogen reduction efficacy. Transfusion 2018;59:1132-46. https://doi.org/10.1111/trf.15103.
-
(2018)
Transfusion
, vol.59
, pp. 1132-1146
-
-
McCullough, J.1
Alter, H.J.2
Ness, P.M.3
-
140
-
-
84897020686
-
Hepatitis E transmission by transfusion of intercept blood system-treated plasma
-
Hauser L1, Roque-Afonso AM, Beylouné A, et al. Hepatitis E transmission by transfusion of intercept blood system-treated plasma. Blood 2014;123:796-7.
-
(2014)
Blood
, vol.123
, pp. 796-797
-
-
Hauser, L.1.1
Roque-Afonso, A.M.2
Beylouné, A.3
-
141
-
-
85066860948
-
-
Mirasol Evaluation of Reduction in Infections Trial (MERIT) [Internet]. Identifier NCT03737669. Bethesda (MD) National Library of Medicine; 2018. Available from, https://clinicaltrials.gov/ct2/show/NCT03737669
-
Mirasol Evaluation of Reduction in Infections Trial (MERIT). ClinicalTrials.gov. Mirasol Evaluation of Reduction in Infections Trial (MERIT) [Internet]. Identifier NCT03737669. Bethesda (MD): National Library of Medicine; 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03737669.
-
-
-
-
142
-
-
84878113969
-
Analysis of reasons for not implementing pathogen inactivation for platelet concentrates
-
Lozano M, Cid J. Analysis of reasons for not implementing pathogen inactivation for platelet concentrates. Transfus Clin Biol 2013;20:158-64.
-
(2013)
Transfus Clin Biol
, vol.20
, pp. 158-164
-
-
Lozano, M.1
Cid, J.2
-
143
-
-
85047087677
-
Special considerations for the use of pathogen reduced blood components in pediatric patients: an overview
-
Goodrich RP, Segatchian J. Special considerations for the use of pathogen reduced blood components in pediatric patients: an overview. Transfus Apher Sci 2018;57:374-7.
-
(2018)
Transfus Apher Sci
, vol.57
, pp. 374-377
-
-
Goodrich, R.P.1
Segatchian, J.2
-
144
-
-
85066847522
-
-
Available from
-
JICA Hands over Blood Safety Technology Project to National Blood Service. National Blood Service Ghana. [cited 2018 Sep 17]. Available from: https://nbsghana.org/jica-hands-over-blood-safety-technology-project-to-national-blood-service/.
-
National Blood Service Ghana. [cited 2018 Sep 17]
-
-
-
145
-
-
84904501752
-
Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment
-
Winter KM, Johnson L, Kwok M, et al. Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment. Transfusion 2014;54:1798-807.
-
(2014)
Transfusion
, vol.54
, pp. 1798-1807
-
-
Winter, K.M.1
Johnson, L.2
Kwok, M.3
-
146
-
-
80054746871
-
Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment
-
North A, Ciaravino V, Mufti N, et al. Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment. Transfusion 2011;51:2208-18.
-
(2011)
Transfusion
, vol.51
, pp. 2208-2218
-
-
North, A.1
Ciaravino, V.2
Mufti, N.3
-
147
-
-
77649191792
-
Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC
-
Mufti NA, Erickson AC, North AK, et al. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010;38:14-9.
-
(2010)
Biologicals
, vol.38
, pp. 14-19
-
-
Mufti, N.A.1
Erickson, A.C.2
North, A.K.3
-
148
-
-
79960186991
-
Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process
-
Cancelas JA, Dumont LJ, Rugg N, et al. Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion 2011;51:2367-76.
-
(2011)
Transfusion
, vol.51
, pp. 2367-2376
-
-
Cancelas, J.A.1
Dumont, L.J.2
Rugg, N.3
-
149
-
-
85042607509
-
Red blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgery
-
Brixner V, Kiessling AH, Madlener K, et al. Red blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgery. Transfusion 2018;58:905-16.
-
(2018)
Transfusion
, vol.58
, pp. 905-916
-
-
Brixner, V.1
Kiessling, A.H.2
Madlener, K.3
-
152
-
-
85061771264
-
The pathogen-reduced red blood cell suspension: single centre study of clinical safety and efficacy in children with oncological and haematological diseases
-
Trakhtman P, Kumukova I, Starostin N, et al. The pathogen-reduced red blood cell suspension: single centre study of clinical safety and efficacy in children with oncological and haematological diseases. Vox Sang 2019;114:223-31.
-
(2019)
Vox Sang
, vol.114
, pp. 223-231
-
-
Trakhtman, P.1
Kumukova, I.2
Starostin, N.3
-
153
-
-
4644239596
-
Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level
-
Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004;80:15-21.
-
(2004)
Photochem Photobiol
, vol.80
, pp. 15-21
-
-
Kumar, V.1
Lockerbie, O.2
Keil, S.D.3
-
154
-
-
79851470298
-
Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light
-
Marschner S, Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011;38:8-18.
-
(2011)
Transfus Med Hemother
, vol.38
, pp. 8-18
-
-
Marschner, S.1
Goodrich, R.2
-
155
-
-
85017742830
-
Red cells from riboflavin plus UV-light treated whole blood can be effectively radiolabeled with 51-Cr for viabiliity studies
-
Cancelas JA, Rugg N, Pratt PG, et al. Red cells from riboflavin plus UV-light treated whole blood can be effectively radiolabeled with 51-Cr for viabiliity studies. Transfusion 2009;49(S3):108A (S44).
-
(2009)
Transfusion
, vol.49
, Issue.S3
, pp. 108A S44
-
-
Cancelas, J.A.1
Rugg, N.2
Pratt, P.G.3
-
156
-
-
79960172472
-
In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood
-
Cancelas JA, Rugg N, Fletcher D, et al. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011;51:1460-8.
-
(2011)
Transfusion
, vol.51
, pp. 1460-1468
-
-
Cancelas, J.A.1
Rugg, N.2
Fletcher, D.3
-
157
-
-
84855854717
-
Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood
-
Tonnetti L, Thorp AM, Reddy HL, et al. Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood. Transfusion 2012;52:409-16.
-
(2012)
Transfusion
, vol.52
, pp. 409-416
-
-
Tonnetti, L.1
Thorp, A.M.2
Reddy, H.L.3
-
158
-
-
84890429898
-
Inactivation of Plasmodium falciparum in whole blood by riboflavin plus irradiation
-
El Chaar M, Atwal S, Freimanis GL, et al. Inactivation of Plasmodium falciparum in whole blood by riboflavin plus irradiation. Transfusion 2013;53:3174-83.
-
(2013)
Transfusion
, vol.53
, pp. 3174-3183
-
-
El Chaar, M.1
Atwal, S.2
Freimanis, G.L.3
-
159
-
-
84873460097
-
Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease?
-
Fast LD, Nevola M, Tavares J, et al. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease? Transfusion 2013;53:373-81.
-
(2013)
Transfusion
, vol.53
, pp. 373-381
-
-
Fast, L.D.1
Nevola, M.2
Tavares, J.3
-
160
-
-
84874794455
-
Development of a riboflavin and ultraviolet light-based device to treat whole blood
-
Reddy HL, Doane SK, Keil SD, et al. Development of a riboflavin and ultraviolet light-based device to treat whole blood. Transfusion 2013;53(Suppl 1):131S-6S.
-
(2013)
Transfusion
, vol.53
, pp. 131S-6S
-
-
Reddy, H.L.1
Doane, S.K.2
Keil, S.D.3
-
161
-
-
84876146438
-
Riboflavin and ultraviolet light reduce the infectivity of Babesia microti in whole blood
-
Tonnetti L, Thorp AM, Reddy HL, et al. Riboflavin and ultraviolet light reduce the infectivity of Babesia microti in whole blood. Transfusion 2013;53:860-7.
-
(2013)
Transfusion
, vol.53
, pp. 860-867
-
-
Tonnetti, L.1
Thorp, A.M.2
Reddy, H.L.3
-
162
-
-
84924603324
-
Large animal evaluation of riboflavin and ultraviolet light-treated whole blood transfusion in a diffuse, nonsurgical bleeding porcine model
-
Okoye OT, Reddy H, Wong MD, et al. Large animal evaluation of riboflavin and ultraviolet light-treated whole blood transfusion in a diffuse, nonsurgical bleeding porcine model. Transfusion 2015;55:532-43.
-
(2015)
Transfusion
, vol.55
, pp. 532-543
-
-
Okoye, O.T.1
Reddy, H.2
Wong, M.D.3
-
163
-
-
84912141075
-
Treatment of whole blood with riboflavin and UV light: impact on malaria parasite viability and whole blood storage
-
Owusu-Ofori S, Kusi J, Owusu-Ofori A, et al. Treatment of whole blood with riboflavin and UV light: impact on malaria parasite viability and whole blood storage. Shock 2015;44(Suppl 1):33-8.
-
(2015)
Shock
, vol.44
, pp. 33-38
-
-
Owusu-Ofori, S.1
Kusi, J.2
Owusu-Ofori, A.3
-
164
-
-
84923040014
-
Reduction of Leishmania donovani infectivity in whole blood using riboflavin and ultraviolet light
-
Tonnetti L, Thorp AM, Reddy HL, et al. Reduction of Leishmania donovani infectivity in whole blood using riboflavin and ultraviolet light. Transfusion 2015;55:326-9.
-
(2015)
Transfusion
, vol.55
, pp. 326-329
-
-
Tonnetti, L.1
Thorp, A.M.2
Reddy, H.L.3
-
165
-
-
85017346266
-
Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage
-
Cancelas JA, Slichter SJ, Rugg N, et al. Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage. Transfusion 2017;57:1218-25.
-
(2017)
Transfusion
, vol.57
, pp. 1218-1225
-
-
Cancelas, J.A.1
Slichter, S.J.2
Rugg, N.3
-
166
-
-
0034912287
-
Inactivation of infectious pathogens in labile blood components: meeting the challenge
-
Corash L. Inactivation of infectious pathogens in labile blood components: meeting the challenge. Transfus Clin Biol 2001;8:138-45.
-
(2001)
Transfus Clin Biol
, vol.8
, pp. 138-145
-
-
Corash, L.1
-
167
-
-
78650315329
-
Helinx technology inactivates pathogens of emerging importance in red blood cell concentrates
-
Dupuis K, Bernard K, Jones S, et al. Helinx technology inactivates pathogens of emerging importance in red blood cell concentrates. Blood 2003;102(Suppl. 1):816a.
-
(2003)
Blood
, vol.102
, pp. 816a
-
-
Dupuis, K.1
Bernard, K.2
Jones, S.3
-
168
-
-
85066848678
-
High titer leukocyte inactivation in INTERCEPT red blood cells (RBC)
-
Hanson D, Propst M, Dupuis K. High titer leukocyte inactivation in INTERCEPT red blood cells (RBC). Vox Sang 2001;101a:81.
-
(2001)
Vox Sang
, vol.101a
, pp. 81
-
-
Hanson, D.1
Propst, M.2
Dupuis, K.3
-
169
-
-
80055013206
-
Inactivation of XMRV in platelet and RBC components prepared with the INTERCEPT blood system
-
Mikovits JA, Hagen K, Liu W, et al. Inactivation of XMRV in platelet and RBC components prepared with the INTERCEPT blood system. Rev Antivir Ther Infect Dis 2010;8:36.
-
(2010)
Rev Antivir Ther Infect Dis
, vol.8
, pp. 36
-
-
Mikovits, J.A.1
Hagen, K.2
Liu, W.3
-
170
-
-
0023992260
-
A new biological target of fucomarians: photochemical formation of covalent adducts with unsaturated fatty acids
-
Specht KG, Kittler L, Midden WR. A new biological target of fucomarians: photochemical formation of covalent adducts with unsaturated fatty acids. Photochem Photobiol 1988;47:537-41.
-
(1988)
Photochem Photobiol
, vol.47
, pp. 537-541
-
-
Specht, K.G.1
Kittler, L.2
Midden, W.R.3
-
171
-
-
33644848731
-
Thiazole orange, a DNA binding photochemical with flexible structure, can inactivate pathogens in red cell suspensions while maintaining red cell storage properties
-
Skripchenko A, Wagner SJ, Thompson-Montgomery D, et al. Thiazole orange, a DNA binding photochemical with flexible structure, can inactivate pathogens in red cell suspensions while maintaining red cell storage properties. Transfusion 2006;46:213-9.
-
(2006)
Transfusion
, vol.46
, pp. 213-219
-
-
Skripchenko, A.1
Wagner, S.J.2
Thompson-Montgomery, D.3
-
172
-
-
52049103376
-
Inactivation of Leishmania donavani infantum and Trypanosoma cruzi in red cell suspensions by thiazole orange
-
Wagner SJ, Skripchenko A, Salata J, et al. Inactivation of Leishmania donavani infantum and Trypanosoma cruzi in red cell suspensions by thiazole orange. Transfusion 2008;48:1363-7.
-
(2008)
Transfusion
, vol.48
, pp. 1363-1367
-
-
Wagner, S.J.1
Skripchenko, A.2
Salata, J.3
-
173
-
-
84874067331
-
Blue light rescues mice from potentially fatal Pseudomonas aeruginosa burn infection: efficacy, safety, and mechanism of action
-
Dai T, Gupta A, Huang YY, et al. Blue light rescues mice from potentially fatal Pseudomonas aeruginosa burn infection: efficacy, safety, and mechanism of action. Antimicrob Agents Chemother 2013;57:1238-45.
-
(2013)
Antimicrob Agents Chemother
, vol.57
, pp. 1238-1245
-
-
Dai, T.1
Gupta, A.2
Huang, Y.Y.3
-
174
-
-
84906048093
-
405 nm light technology for the inactivation of pathogens and its potential role for environmental disinfection and infection control
-
Maclean M, McKenzie K, Anderson JG, et al. 405 nm light technology for the inactivation of pathogens and its potential role for environmental disinfection and infection control. J Hosp Infect 2014;88:1-11.
-
(2014)
J Hosp Infect
, vol.88
, pp. 1-11
-
-
Maclean, M.1
McKenzie, K.2
Anderson, J.G.3
-
175
-
-
85032853700
-
A new proof-of-concept in bacterial reduction: antimicrobial action of violet-blue light (405 nm) in ex vivo stored plasma
-
Maclean M, White T, Anderson JG, et al. A new proof-of-concept in bacterial reduction: antimicrobial action of violet-blue light (405 nm) in ex vivo stored plasma. J Blood Transfus 2016;2016:2920514.
-
(2016)
J Blood Transfus
, vol.2016
, pp. 2920514
-
-
Maclean, M.1
White, T.2
Anderson, J.G.3
-
176
-
-
63849253384
-
Inactivation of bacterial pathogens following exposure to light from a 405-nm LED array
-
Maclean M, MacGregor SJ, Anderson JG, et al. Inactivation of bacterial pathogens following exposure to light from a 405-nm LED array. Appl Environ Microbiol 2009;75:1932-7.
-
(2009)
Appl Environ Microbiol
, vol.75
, pp. 1932-1937
-
-
Maclean, M.1
MacGregor, S.J.2
Anderson, J.G.3
-
177
-
-
85007490527
-
Investigating the influence of biologically-relevant suspending media on 405 nm light inactivation of feline calicivirus: a surrogate of norovirus
-
Tomb RM, Maclean M, JE Coia E, et al. Investigating the influence of biologically-relevant suspending media on 405 nm light inactivation of feline calicivirus: a surrogate of norovirus. Food Environ Virol 2017;9:159-67.
-
(2017)
Food Environ Virol
, vol.9
, pp. 159-167
-
-
Tomb, R.M.1
Maclean, M.2
JE Coia, E.3
-
179
-
-
85060543482
-
Cold-stored platelets: A product with function optimized for hemorrhage control
-
Reddoch-Cardenas KM, Bynum JA, Meledeo MA, et al. Cold-stored platelets: A product with function optimized for hemorrhage control. Transfus Apher Sci 2019;58:16-22.
-
(2019)
Transfus Apher Sci
, vol.58
, pp. 16-22
-
-
Reddoch-Cardenas, K.M.1
Bynum, J.A.2
Meledeo, M.A.3
-
180
-
-
0037428090
-
The clearance mechanism of chilled blood platelets
-
Hoffmeister KM, Felbinger TW, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell 2003;112:87-97.
-
(2003)
Cell
, vol.112
, pp. 87-97
-
-
Hoffmeister, K.M.1
Felbinger, T.W.2
Falet, H.3
-
181
-
-
85040778532
-
Transfusion with cold stored platelets in patients undergoing complex cardiothoracic surgery with cardiopulmonary bypass circulation: effect on bleeding and thromboembolic risk
-
Apelseth TO, Kristoffersen EK, Kvalheim VL, et al. Transfusion with cold stored platelets in patients undergoing complex cardiothoracic surgery with cardiopulmonary bypass circulation: effect on bleeding and thromboembolic risk. Transfusion 2017;57:3A-4A.
-
(2017)
Transfusion
, vol.57
, pp. 3A-4A
-
-
Apelseth, T.O.1
Kristoffersen, E.K.2
Kvalheim, V.L.3
-
182
-
-
85057869101
-
The impact of refrigerated storage of UVC pathogen inactivated platelet concentrates on in vitro platelet quality parameters
-
Johnson L, Cameron M, Waters L, et al. The impact of refrigerated storage of UVC pathogen inactivated platelet concentrates on in vitro platelet quality parameters. Vox Sang 2019;114:47-56.
-
(2019)
Vox Sang
, vol.114
, pp. 47-56
-
-
Johnson, L.1
Cameron, M.2
Waters, L.3
-
183
-
-
85048143148
-
Refrigeration, cryopreservation and pathogen inactivation: an updated perspective on platelet storage conditions
-
Waters L, Cameron M, Padula MP, et al. Refrigeration, cryopreservation and pathogen inactivation: an updated perspective on platelet storage conditions. Vox Sang 2018;113:317-28.
-
(2018)
Vox Sang
, vol.113
, pp. 317-328
-
-
Waters, L.1
Cameron, M.2
Padula, M.P.3
-
184
-
-
84872232512
-
Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time
-
Pidcoke HF, McFaul SJ, Ramasubramanian AK, et al. Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time. Transfusion 2013;53(Suppl 1):137S-49S.
-
(2013)
Transfusion
, vol.53
, pp. 137S-49S
-
-
Pidcoke, H.F.1
McFaul, S.J.2
Ramasubramanian, A.K.3
-
185
-
-
85073836758
-
Hemostatic functional preservation of refrigerated whole blood over 35 days
-
Meledeo MA, Peltier GC, McIntosh CS, et al. Hemostatic functional preservation of refrigerated whole blood over 35 days. Transfusion 2018;58:62A.
-
(2018)
Transfusion
, vol.58
, pp. 62A
-
-
Meledeo, M.A.1
Peltier, G.C.2
McIntosh, C.S.3
-
186
-
-
79955852870
-
Lyophilized platelets: challenges and opportunities
-
Cap AP, Perkins JG. Lyophilized platelets: challenges and opportunities. J Trauma 2011;70(5 Suppl):S59-60.
-
(2011)
J Trauma
, vol.70
, Issue.5
, pp. S59-60
-
-
Cap, A.P.1
Perkins, J.G.2
-
187
-
-
84961807639
-
Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro
-
Cap AP, Pidcoke HF, Keil SD, et al. Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro. Transfusion 2016;56(Suppl 1):S6-15.
-
(2016)
Transfusion
, vol.56
, pp. S6-15
-
-
Cap, A.P.1
Pidcoke, H.F.2
Keil, S.D.3
|